Dr. Xiao Juan is a Chief Physician and Ward Director of Ward 9 in the Hematology Oncology Center at Beijing Jingdu Children's Hospital, a leading institution in China's pediatric hematology oncology field. With nearly 20 years of clinical experience, she has become an authoritative expert in hematopoietic stem cell transplantation (HSCT) and the treatment of refractory childhood blood diseases.
Graduating from Tongji Medical College of Huazhong University of Science and Technology (a renowned higher education institution in China) with a Doctor of Medicine degree, Dr. Xiao further honed her professional skills at Wuhan Union Hospital and Beijing Daopei Hospital (both renowned centers in hematology and transplantation). A notable achievement in her career is establishing Ward 9 as a core hub for managing high-risk cases, including relapsed leukemia, infant leukemia, hemophagocytic lymphohistiocytosis (HLH), and chronic active Epstein-Barr virus (EBV) infection.
Dr. Xiao's professional scope covers the diagnosis, chemotherapy, and transplantation treatment of high-risk pediatric blood and immune diseases, specifically including:
Hematopoietic Stem Cell Transplantation (HSCT):
High-risk leukemia (relapsed/refractory cases)
Bone marrow failure diseases: congenital bone marrow failure, severe aplastic anemia, myelodysplastic syndromes (MDS), etc.
Hemophagocytic lymphohistiocytosis (HLH): primary HLH, EBV-associated HLH, chronic active EBV infection
Precision Chemotherapy and Immunotherapy:
Various types of leukemia/lymphoma
Non-Hodgkin Lymphoma (NHL)
Infant leukemia
Proficient in various cellular therapies such as CAR-T and NK cell therapy
Common Pediatric Blood Diseases:
Various anemias
Immune thrombocytopenic purpura (ITP), etc.
Current Position: Director of Ward 9, Hematology Oncology Center, Beijing Kyoto Children's Hospitall
Principal Investigator of multiple national and ministerial research projects on hematopoietic stem cell transplantation and immunotherapy
Committee Member of the Pediatric Hereditary Blood Diseases Branch of Beijing Biological Products Association
Council Member of the Pediatric Branch of the China Association of Chinese Medical Information
Committee Member of the Health Science Popularization Branch of the China Population Culture Promotion Association
Wuhan Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology – clinical work in the Department of Hematologyn
Tongji Medical College, Huazhong University of Science and Technology
Beijing Daopei Hospital – hematopoietic stem cell transplantation for benign and malignant pediatric blood system diseases
4SCAR2.0 therapy for the management of post transplantation relapse of B-cell acute lymphoblastic leukemia. Frontiers in Hematology, 2:1251622. doi: 10.3389/frhem.2023.1251622.l
Lack of surgical resection is associated with increased early mortality in hematological patients complicated with rhino-orbital-cerebral mucormycosis. Annals of Hematology, 2023, volume 102, 2933–2942.l
Modified G-CSF/ATG-Based Haploidentical Transplantation Protocol in Pediatric Primary Hemophagocytic Lymphohistiocytosis: A Long-Term Follow-Up Single-Center Experience. Pediatr Blood Cancer. 2024 Dec 20:e31495. doi: 10.1002/pbc.31495.l
2020: The paper Clinical Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Hemophagocytic Syndrome with Central Nervous System Lesions won an Excellent Paper Award at the 25th National Academic Conference on Pediatrics of the Chinese Medical Association.l
2021: The paper Donor-Derived CAR-T Cell Therapy for Relapsed B-Cell Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation in Children won an Excellent Paper Award at the National Academic Conference on Pediatric Hematology and Oncology.l
2023: The paper Clinical Analysis and Single-Center Efficacy Report of Relapsed/Refractory Acute B Lymphoblastic Leukemia in Children won an Excellent Paper Award at the 28th National Academic Conference on Pediatrics of the Chinese Medical Association.
Mandarin and English
Selected authentic reviews:l "Dr. Xiao saved our child’s life after multiple relapses. Her expertise in transplantation gave us hope." (Parent of an HLH survivor, 2024)l "She patiently and clearly explained complex treatment plans, and we fully trust her." (Parent of a leukemia patient, 2023)l Core evaluation: Clinical competence and compassionate communication rated 4.9/5.
Professional InfluenceDr. Xiao Juan embodies the integration of academic rigor and clinical innovation, advancing the development of pediatric hematopoietic stem cell transplantation and cellular immunotherapy. Under her leadership at Beijing Kyoto Children's Hospital, Ward 9 has become a national referral center for highly complex blood disease cases.
EN
CN
